vTv Therapeutics (NASDAQ:VTVT) Stock Rating Lowered by Zacks Research

vTv Therapeutics (NASDAQ:VTVT) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Evercore assumed coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target on the stock. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Finally, BTIG Research reaffirmed a “buy” rating and set a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $53.00.

vTv Therapeutics Price Performance

Shares of NASDAQ:VTVT opened at $32.76 on Thursday. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00. The company has a market capitalization of $129.07 million, a P/E ratio of -35.23 and a beta of 0.27. The firm’s 50 day simple moving average is $34.70 and its two-hundred day simple moving average is $35.04.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.21 by $1.44. The firm had revenue of $36.84 million for the quarter, compared to analysts’ expectations of $20.00 million. On average, sell-side analysts anticipate that vTv Therapeutics will post -2.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On vTv Therapeutics

Several hedge funds have recently modified their holdings of the stock. Baker BROS. Advisors LP lifted its holdings in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. 683 Capital Management LLC purchased a new position in shares of vTv Therapeutics in the fourth quarter worth $731,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics in the fourth quarter worth $221,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.